Marvin L. White, Executive Chair
Mr. White serves as the Executive Chair of Aptevo and previously served as President and Chief Executive Officer. Previously, Mr. White served as Chief Financial Officer of St. Vincent Health, and was responsible for finance, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to St. Vincent Health, Mr. White served as Chief Financial Officer of LillyUSA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking. Prior to his career in healthcare, Mr. White held leadership positions at General Motors, Hewlett-Packard, and Motorola, including financial roles within its Japan, South Asia, and Latin America Cellular Group. He is currently a Director of the Board at OneAmerica Financial Partners, Delta Dental of Washington and Emergent Biosolutions. Mr. White earned his B.S. in Accounting from Wilberforce University, an HBCU, and received an M.B.A. in Finance from Indiana University where he was awarded the Consortium Fellowship.

John E. Niederhuber, M.D., Lead Independent Director
Dr. Niederhuber serves Aptevo as Lead Independent Director and is the immediate past Chairman of the Board. Dr. Niederhuber is currently Adjunct Professor of Surgery and Oncology the Johns Hopkins University School of Medicine and Deputy Director of the Johns Hopkins Clinical Research Network. He retired in April 2019 from his position as Executive Vice President Inova Health System, Fairfax, Virginia where he served (2010-2019) as the Chief Executive Officer and founder of the Inova Translational Medicine Institute, a not-for-profit genomics research institute. Dr. Niederhuber served as a director of Emergent from August 2010, until his resignation from the Emergent Board of Directors in May 2016. Dr. Niederhuber is the former Director of the National Cancer Institute (NCI), of the National Institutes of Health having been appointed to that position in 2006 by President Bush. Before assuming the NCI directorship, he chaired the National Cancer Advisory Board. Dr. Niederhuber has held a number of academic leadership positions including as Director of the University of Wisconsin Comprehensive Cancer Center and professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine from 1997 to 2005. He chaired the Department of Surgery at Stanford University School of Medicine from 1991 to 1997 and held professorships at the Johns Hopkins University School of Medicine from 1987 to 1991 and at the University of Michigan from 1973 to 1987 where he also served as Associate Dean for Research and Associate Dean Clinical Affairs. Dr. Niederhuber is a member of the National Academy of Medicine.

Daniel J. Abdun-Nabi
Mr. Abdun-Nabi served as the President and Chief Executive Officer of Emergent BioSolutions from April 2010 until his retirement from Emergent in April 2019. From May 2007 to March 2012, Mr. Abdun-Nabi served as Emergent’s President and Chief Operating Officer. Mr. Abdun-Nabi previously served as Emergent’s Corporate Secretary from December 2004 to January 2008, Emergent’s Senior Vice President, Corporate Affairs and General Counsel from December 2004 to April 2007 and Emergent’s Vice President and General Counsel from May 2004 to December 2004. Mr. Abdun-Nabi served as General Counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004.

Grady Grant, III
Mr. Grant has over 35 years of experience in pharmaceutical sales and marketing. He is EVP/ Partner for Vanigent BioPharm, start-up Contract Sales Organization for the pharmaceutical space. Prior to this role, he served as EVP for Evolve Biosystems, a company that specializes in providing microbiome products that restore healthy gut flora. He served as consultant Chief Commercial Officer for Unpharma LLC, a commercial manufacturing organization specializing in Blo-Fill seal technology utilized in pharmaceutical as well as OTC formulations. Prior to this role, he served as Vice President of Sales for Tissue Tech Limited, an organization who pioneered the innovative application of human placental tissue in wound healing. From December 2011 to August 2018, he worked as Vice President of Medical Sales for Mead Johnson Nutrition, a public company focused on pediatric nutrition in the retail and medical setting. His tenure at Mead Johnson was preceded by 30 years of service at Eli Lilly and Company where he held various leadership positions in sales and marketing concluding his career as Vice President of Sales Neuroscience which he held from January 2006 to December 2011. Mr. Grant is a NACD certified Director.

Zsolt Harsanyi, Ph.D.
Dr. Harsanyi serves as Chairman of the Board at Emergent BioSolutions. Dr. Harsanyi served as Chairman of the Board of N-Gene Research Laboratories, Inc., a privately held biotechnology company, from 2011-2024. Dr. Harsanyi also served as Chief Executive Officer and Chairman of the Board of Directors of Exponential Biotherapies Inc., a private biotechnology company, from December 2004 to February 2011. Dr. Harsanyi served as President of Porton International plc, or Porton International, a pharmaceutical and vaccine company, from January 1983 to December 2004. Dr. Harsanyi was a founder of Dynport Vaccine Company LLC in September 1996. Prior to joining Porton International, Dr. Harsanyi was Vice President of Corporate Finance at E.F. Hutton, Inc. Previously, Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress’ Office of Technology Assessment, served as a consultant to the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell University Medical College.

Barbara Lopez Kunz
Barbara Lopez Kunz serves as CEO of Caidya and brings more than 30 years of global leadership experience spanning life sciences, clinical research, diagnostics, and public health. Known for her strategic foresight and people-centered leadership, she has served on Caidya’s board since 2022, playing a key role in shaping corporate governance and long-term strategy.

Before joining Caidya, Barbara was President and CEO of the Drug Information Association (DIA), where she led a digital and organizational transformation that deepened global regulatory engagement. At Battelle, she oversaw a billion-dollar global health and life sciences portfolio, accelerating growth across public health, clinical research, and medical devices. Earlier in her career, she held executive roles at Thermo Fisher Scientific, where she advanced the biosciences division through targeted M&A, and at DuPont, where she served as General Manager. She began her career at ICI in as research scientist before quickly transitioning into broader global leadership positions.

Barbara currently serves on the board of Werfen and as vice chair of the board at Children’s National Hospital.

She holds a Master of Science in Polymer Science from the University of Akron and graduated from International Executive Program at INSEAD. She is a DIA Fellow and holds a corporate governance certification from the National Association of Corporate Directors.